Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2010

Brody Joshua D, Ai Weiyun Z, Czerwinski Debra K, Torchia James A, Levy Mia, Advani Ranjana H, Kim Youn H, Hoppe Richard T, Knox Susan J, Shin Lewis K, Wapnir Irene, Tibshirani Robert J, Levy Ronald

Abstract excerpt

PURPOSE: Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors. PATIENTS AND METHODS: We treated 15...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Immunity, Innate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Logistic Models

Share to Lymphoma, B-Cell

Share to Oligodeoxyribonucleotides

Share to Proportional Hazards Models

Share to Remission Induction

Share to Toll-Like Receptor 9

Source

Open in PubMed Open full text

Identifiers

PMID: 20697067
DOI: 10.1200/JCO.2010.28.9793
PMCID: PMC2954133

Genes

TLR9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.PMID 20697067Read ↗

First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphomaSemantic proximity Read ↗

In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapySemantic proximity Read ↗

B cells imprint adoptively transferred CD8 <sup>+</sup> T cells with enhanced tumor immunitySemantic proximity Read ↗

Adoptive transfer of T lymphocytes retrovirally transduced to express personalized neoantigen reactive T cell receptors can mediate tumor regression in patients with metastatic colorectal cancerSemantic proximity Read ↗

Adoptive In Situ Vaccination with Cyclical Intermittent Stereotactic Body Radiotherapy (SBRT) and Immunotherapy – a Review and Proposed StrategySemantic proximity Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

Specifically activated dendritic cells--cell-based vaccine against lymphosarcoma exhibiting multiple drug resistance phenotype.Semantic proximity Read ↗

Active immunization against cancer with dendritic cells: the near future.Semantic proximity Read ↗

Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Semantic proximity Read ↗

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.Semantic proximity Read ↗

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapySemantic proximity Read ↗

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.